Previous Article | Next Article 
Journal of Virology, December 2000, p. 11329-11338, Vol. 74, No. 23
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Canarypox Virus-Induced Maturation of Dendritic Cells Is
Mediated by Apoptotic Cell Death and Tumor Necrosis Factor
Alpha Secretion
Ralf
Ignatius,1,
Mary
Marovich,2
Erin
Mehlhop,1
Loreley
Villamide,1
Karsten
Mahnke,1
William I.
Cox,3
Frank
Isdell,1
Sarah S.
Frankel,2
John R.
Mascola,2
Ralph M.
Steinman,1 and
Melissa
Pope1,*
Laboratory of Cellular Physiology and
Immunology, The Rockefeller University, New York, New York
100211; Division of Retrovirology,
Walter Reed Army Institute of Research and Henry M. Jackson
Foundation, Rockville, Maryland 208502; and
Virogenetics Corporation, Rensselaer Technology Park, Troy,
New York 121803
Received 23 August 2000/Accepted 1 September 2000
 |
ABSTRACT |
Recombinant avipox viruses are being widely evaluated as vaccines.
To address how these viruses, which replicate poorly in mammalian
cells, might be immunogenic, we studied how canarypox virus (ALVAC)
interacts with primate antigen-presenting dendritic cells (DCs). When
human and rhesus macaque monocyte-derived DCs were exposed to
recombinant ALVAC, immature DCs were most susceptible to infection.
However, many of the infected cells underwent apoptotic cell death, and
dying infected cells were engulfed by uninfected DCs. Furthermore, a
subset of DCs matured in the ALVAC-exposed DC cultures. DC maturation
coincided with tumor necrosis factor alpha (TNF-
) secretion and was
significantly blocked in the presence of anti-TNF-
antibodies.
Interestingly, inhibition of apoptosis with a caspase 3 inhibitor also
reduced some of the maturation induced by exposure to ALVAC. This
indicates that both TNF-
and the presence of primarily apoptotic
cells contributed to DC maturation. Therefore, infection of immature
primate DCs with ALVAC results in apoptotic death of infected cells,
which can be internalized by noninfected DCs driving DC maturation in
the presence of the TNF-
secreted concomitantly by exposed cells.
This suggests an important mechanism that may influence the
immunogenicity of avipox virus vectors.
 |
INTRODUCTION |
Recombinant avipox viruses,
such as canarypox virus (ALVAC) or fowlpox virus, are of
special interest in the field of vaccine development (reviewed in
reference 38). These vectors are safe, since their
replication is restricted to avian hosts. Even in immunocompromised
mammalian hosts, systemic spread does not occur (57). In
addition, they are large enough to be efficiently loaded with genes of
different infectious or tumor agents. Finally, they can elicit immune
responses in people previously exposed to vaccinia virus circumventing
potential anti-vector immune responses in vaccinia virus-immune persons
(10). Thus, avipox viruses provide a potentially useful
vehicle to safely induce immune responses against a variety of antigens.
Since ALVAC has been shown to be more efficacious than a fowlpox
virus-based vector, providing a comparable protective effect to that of
a thymidine kinase-disrupted replication-competent vaccinia virus
vector (58), many studies using different ALVAC constructs
have been performed. ALVAC constructs encoding foreign proteins have
been shown to induce humoral and cellular immune responses against a
variety of infectious pathogens. These include rabies virus (19,
58), feline immunodeficiency virus (59), human
immunodeficiency virus type (HIV-1) and HIV-2 (1, 4, 6, 15, 18,
35, 49), Japanese encephalitis virus (32, 43), rabbit
hemorrhagic disease virus (17), and canine distemper virus
(CDV) (39, 55), as well as tumor antigens (25, 34, 46). In fact, very recent studies revealed that mucosal
application of ALVAC containing CDV genes induced high titers of
neutralizing antibodies (Abs) and protection against a mucosal
challenge with CDV (63). To potentially optimize the vaccine
efficiency of ALVAC, we were particularly interested in how the virus
imparts immunity in mammalian hosts without extensive replication,
tissue damage, and subsequent spread of infection between cells.
Dendritic cells (DCs) are potent antigen-presenting cells central to
immune activation and exist in an immature state at body surfaces and
mucosal sites. Immature DCs can capture antigens such as extracellular
and facultative intracellular bacteria, parasites, and dying cells
(reviewed in references 5 and
54). This is followed by migration to the draining
lymph nodes, where as mature DCs they present the antigen to
lymphocytes. Furthermore, DCs express a variety of surface molecules
necessary for the entry of viruses, such as CD4, chemokine receptors,
for HIV and simian immunodeficiency virus (SIV), CD46 for measles virus
(5), and DC-SIGN for the binding of HIV (22).
Therefore, they can directly be infected by these and other viruses.
Since direct targeting of DCs with ALVAC might enhance immune responses
against ALVAC-encoded antigens, we investigated the consequences of the
interaction of ALVAC with DCs. While both immature and mature DCs were
infected with ALVAC, immature DCs were more sensitive to infection.
Many ALVAC-infected immature DCs rapidly underwent apoptotic cell
death, and endocytosis of infected, dead or dying DCs by uninfected
immature DCs was observed. Concurrently, a subpopulation of
ALVAC-exposed DCs matured. Maturation was largely driven by the tumor
necrosis factor alpha (TNF-
) secreted following exposure to ALVAC
and partially by the ingestion of infected cell debris. These data
suggest a mechanism for ALVAC-induced DC maturation, which involves
apoptosis and TNF-
secretion, and this mechanism may augment the
presentation of virus-encoded antigens and thereby have a significant
impact on the efficiency of these viruses in vaccine development.
 |
MATERIALS AND METHODS |
Viral constructs.
All ALVAC constructs used in this study
were engineered at Virogenetics, Troy, N.Y. Constructs include the
strain vCP172, containing the sequence for the SIV gag
(encoding for the SIV core protein p27) and pol (encoding
for the viral reverse transcriptase and integrase), vCP180, which
contains in addition to SIV gag-pol the gene for the viral
envelope (env), vCP205 (HIV gag, protease, and
env) and the parental strain (ALVAC). Heat-inactivated virus was obtained by incubating virus at 56°C for 30 min. Successful inactivation was confirmed by a lack of protein expression by DCs
exposed to the heat-inactivated virus (data not shown). ALVAC was UV
inactivated in 1 mM Tris in a 35-mm dish for 10 min with constant
stirring. Inactivation was confirmed by performing a standard virus
titration plaque assay.
Culture medium.
RPMI 1640 (Cellgro; Fisher Scientific,
Springfield, N.J., or BioWhittaker, Walkersville, Md.), supplemented
with 2 mM L-glutamine (GIBCO-BRL/Life Technologies
[GIBCO-BRL], Grand Island, N.Y.), 50 µM 2-mercaptoethanol (Sigma
Chemical Company, St. Louis, Mo.), 10 mM HEPES (GIBCO-BRL), penicillin
(100 U/ml)-streptomycin (100 µg/ml) (GIBCO-BRL), and 1% human plasma
(heparinized) or 10% heat-inactivated fetal calf serum (PAA
Laboratories, Parker Ford, Pa.) screened negative for virus,
mycoplasma, and below the detection limits for endotoxin.
Generation of human and macaque DCs.
Heparinized human blood
was obtained from healthy donors or as leukopaks from the New York City
Blood Bank or RH Labs, Baltimore, Md. Peripheral blood mononuclear
cells (PBMCs) were isolated by centrifugation on Ficoll-Hypaque
(Amersham Pharmacia Biotech AB, Uppsala, Sweden). T cells were removed
by adhering 8 × 106 cells/well in a six-well tray
(Falcon, Lincoln Park, N.Y.) for 1 to 2 h at 37°C. Nonadherent T
cells were carefully washed away, and adherent monocytes were cultured
for 6 to 7 days in 3 ml of medium containing 100 U of interleukin-4
(IL-4; R&D Systems, Minneapolis, Minn.) per ml and 1,000 U of
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Immunex,
Seattle, Wash.). In some experiments, immature human DCs were generated
from a highly enriched population of CD14+ cells obtained
by the magnetic bead selection of monocytes (Miltenyi Biotec, Auburn,
Calif.). The cells were placed into tissue culture flasks or six-well
plates at 106 cells/ml and cultured for 6 to 7 days in the
presence of 100 to 1,000 U of IL-4 and 1,000 U of GM-CSF per ml.
Heparinized rhesus macaque (Macaca mulatta) blood was
obtained from adult animals. All animals tested negative for Abs to SIV, type D retroviruses, and simian T-lymphotropic virus type 1, and
were housed at the Tulane Regional Primate Research Center or the
animal facilities at the Walter Reed Army Institute for Research.
Animal care operations were in compliance with the regulations detailed
under the animal welfare act, and in the Guide for the Care and
Use of Laboratory Animals. PBMCs were separated by centrifugation on Ficoll-Hypaque. A total of 12 × 106 to 15 × 106 PBMCs were plated per well of a six-well tray and
incubated for 1 to 2 h at 37°C. After careful removal of
nonadherent cells (by washing with warm phosphate-buffered saline
[PBS]), the adherent monocytes were cultured for 6 to 7 days in the
presence of 100 U of IL-4 and 1,000 U of GM-CSF per ml. In some
experiments, CD14+ monocytes were selected using the
magnetic activated cell sorting (MACS) system (Miltenyi Biotec), plated
at 106 cells/ml in six-well plates, and cultured in the
presence of GM-CSF and IL-4 (see above).
For both human and monkey DCs, additional cytokines were added on days
2, 4, and 6. Immature DCs were obtained after the 6
to 7 days in
culture with GM-CSF and IL-4. To generate mature
DCs, 50% of the
medium was substituted with monocyte-conditioned
medium (MCM) on day 6 or 7, and the cells cultured for an additional
2 days. When immature
and mature DCs were directly compared, immature
DCs were cultured for
the additional 2 days in the absence of
MCM. MCM was generated using a
slightly modified protocol from
that previously described
(
45). Briefly, bacteriologic dishes
(Falcon) were coated
with 4 ml of a 100-µg/ml concentration of
human gamma globulin (Bayer
Corp., Elkhart, Ind.) in PBS and incubated
for 10 min at room
temperature before being washed four times
with PBS. Then, 9 × 10
7 human PBMCs were plated in each dish and incubated for
1 h at
37°C. Nonadherent cells were removed, 8 ml of fresh
medium was
added, and the dishes were incubated for 24 h at
37°C. The 24-h
cell-free supernatants were pooled, filtered, and
frozen at

20°C
before
use.
The phenotype of the DCs was routinely monitored by two-color
fluorescence-activated cell sorter (FACS) analysis on a FACScan
flow
cytometer (Becton Dickinson, Mountainview, Calif.). Fluorescein
isothiocyanate (FITC)-conjugated monoclonal Abs (MAbs) against
human
major histocompatibility complex (MHC) class II (anti-HLA-DR-FITC)
(Becton Dickinson Immunocytometry Systems [BDIS], San Jose, Calif.)
were used in combination with phycoerythrin (PE)-conjugated MAbs
against human CD25 (BDIS), CD80 (BDIS), CD83 (Coulter Corp., Miami,
Fla.), and CD86 (PharMingen, San Diego, Calif.). Immature DCs
typically
were HLA-DR
++, CD86
++, CD80
+/low,
CD83
/weak, and CD25

, while mature DCs
expressed HLA-DR
+++, CD86
+++,
CD25
++, CD80
++, and CD83
++.
Infection of DCs with ALVAC.
DCs were counted and cultured
at 105 large cells/well in 96-well round-bottom trays
(Linbro). Either the original culture medium in which the DCs were
generated (original medium) was reused without the addition of fresh
cytokines or else fresh medium was prepared that contained 100 U of
IL-4 and 1,000 U of GM-CSF per ml. DCs were infected with the indicated
ALVAC construct at a multiplicity of infection (MOI) of 5 to 10. Where
indicated, the cells were washed twice after 1 h at 37°C before
being cultured for up to 4 days. When mature and immature DCs were
compared, both DC preparations were resuspended in original medium. The
DC phenotype was monitored by FACS analysis prior to and at various
times after exposure to ALVAC. Uninfected control DCs were included and
analyzed for comparison.
Alternatively, 2 × 10
6 to 5 × 10
6
immature human DCs were resuspended in 0.1 ml of culture medium in
15-ml conical tubes and
incubated with vCP205 (MOI of 0.2 to 10) for
2 h at 37°C. Cells
were washed and placed at 10
6
cells/ml in a 24-well plate (Costar; Corning, Inc., Corning,
N.Y.).
After 24 h, cell supernatants were collected and stored
at

70°C for subsequent cytokine analysis. At the same time, DCs
were
harvested and counted and the viability was monitored by
trypan blue
staining.
In some experiments, ALVAC-infected or uninfected immature DCs (1 × 10
5 to 2 × 10
5) were placed into the
wells of a 96-well culture tray (Millipore
Multiscreen Filtration
System, MAMCS9610). The upper filtration
plate (Millipore MACMS4510)
was positioned onto the culture tray,
and uninfected DCs in
cytokine-containing medium were then placed
at various concentrations
into the upper wells. The plates were
cultured for up to 4 days at
37°C, and the DCs were collected
from the upper (uninfected cells)
and lower (infected versus uninfected
cells) chambers at specific time
points for FACS
analysis.
Identification of ALVAC infection.
In order to identify
recombinant ALVAC-infected cells, cells were stained intracellularly
using a polyclonal rabbit anti-canarypox virus serum (Virogenetics) at
a 1:10,000 dilution. Cells were washed twice and fixed in 4%
paraformaldehyde-PBS (wt/vol) for 10 min at 4°C. After two washes,
cells were incubated in 1% saponin (Sigma) for 30 min at 4°C, washed
twice with PBS, and resuspended in 100 µl of 0.1% saponin containing
the diluted rabbit serum. After 30 min of incubation at 4°C, the
cells were washed twice with 0.1% saponin, resuspended in 100 µl of
0.1% saponin containing an FITC-conjugated donkey anti-rabbit
immunoglobulin (Jackson ImmunoResearch Laboratories, West Grove, Pa.)
at a 1:200 dilution, and incubated for 30 min at 4°C. Finally, cells
were washed twice and monitored by FACS. Background staining was
monitored on uninfected cells from the same donor and on cells
incubated with normal rabbit immunoglobulin.
To detect expression of SIV proteins in infected cells, the viral
constructs vCP172 (SIV
gag and
pol) or vCP180
(SIV
gag,
pol, and
env) were used.
Using the anti-SIV p27 MAb 55-2F12 (NIH
AIDS Research and Reference
Reagent Program), infection was monitored
either by immunoperoxidase
staining on cytospin preparations as
described previously
(
26) or by intracellular FACS staining
(see above). Here,
biotinylated anti-SIV p27 MAb was used at a
1:400 dilution, and
Fluorescein (DTAF)-conjugated streptavidin
(Jackson ImmunoResearch) was
used at 1:200.
To detect HIV p24, infected DCs were fixed and permeabilized using a
2% formaldehyde-0.1% saponin buffer. After a 20-min incubation,
the
cells were washed in ice-cold PBS-0.1% saponin. The cells
were then
incubated with a murine anti-p24 MAb (Dako, Carpinteria,
Calif.) or the
isotype control (Southern Biotechnology Associates,
Birmingham, Ala.)
at a 1:10 dilution followed by a PE-conjugated
goat anti-mouse
immunoglobulin (Southern Biotechnology Associates)
at 1:200.
Apoptosis assays.
Apoptotic cells were identified using the
TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick end
labeling) technique, and assays were performed according to the
manufacturer's guidelines (Boehringer Mannheim and Roche Molecular
Biochemicals, Indianapolis, Ind.). In brief, cells were harvested at
different time points after infection, washed twice with PBS in a
96-well V-bottomed tray (Linbro), and fixed in 4%
paraformaldehyde-PBS (wt/vol) for 30 min at room temperature. After
centrifugation (2,000 rpm for 2 to 3 min), cells were washed once with
200 µl of PBS, resuspended in 100 µl of permeabilization solution
(0.1% Triton X-100 in 0.1 sodium citrate), and incubated for 2 min at
4°C. The cells were washed twice (2,000 rpm for 2 to 3 min) using
cold PBS, resuspended in 50 µl of TUNEL reaction or control mixture,
and incubated for 60 min at 37°C in 5% CO2. Cells were
washed twice in PBS and analyzed by FACS.
Fluorescent labeling of DCs.
DCs were stained with the green
fluorescent dye, 5-chloromethylfluorescein diacetate (CMFDA), or the
red fluorescent dye, 5-(and-6)-{[(4-chloromethyl)
benzoyl]amino}tetramethylrhodamine (CMTMR) (Molecular Probes,
Eugene, Oreg.) according to the manufacturers' instructions. Cells
were placed into a 1.5-ml Eppendorf tube, centrifuged, and resuspended
in 100 µl of prewarmed (37°C) probe-containing (5 µM) RPMI. After
15 min at 37°C, the DCs were centrifuged, resuspended in prewarmed
medium, and incubated for an additional 30 min at 37°C. The cells
were centrifuged once more and then counted prior to use.
Confocal microscopy.
CMTMR (red)-stained infected DCs and
CMFDA (green)-stained, uninfected DCs were cocultured at a ratio of 1:1
for 2 to 3 days. After culture, the cells were seeded in serum-free
RPMI into alcian blue (Sigma) coated Lab Tek tissue culture chambers
(Nunc, Naperville, Ill.) (27) at a minimum number of
104 cells/chamber. The chambers were incubated for 1 h
at 37°C, the medium was aspirated, and the adhered cells were
immediately fixed with 4% paraformaldehyde-PBS (wt/vol) for 20 min at
room temperature. Specimens were examined by confocal laser scan
microscopy (Zeiss) using adequate filter settings for
fluorescein-rhodamine excitation and emission, respectively. Optical
sections were approximately 0.75 µm thick, and images were overlaid
using the microscope software provided by Zeiss.
Inhibition of apoptosis.
Apoptosis of infected cells was
inhibited using the Caspase-3/CPP32 inhibitor Z-DEVD-FMK (Kamiya
Biomedical Company, Seattle, Wash.) (28). Stock solutions
(100 mM) of Z-DEVD-FMK in dimethyl sulfoxide (DMSO) were stored at
4°C. DCs were preincubated with Z-DEVD-FMK at a concentration of 250 or 500 µM for 30 min at 37°C in 5% CO2 before
infection with recombinant ALVAC. To ensure that the drug did not
interfere with DC maturation per se, a separate aliquot of DCs was
pretreated with Z-DEVD-FMK prior to addition of MCM as the maturation stimulus.
TNF-
assays.
Cell supernatants were collected from
ALVAC-exposed and unexposed DC cultures after 1 to 4 days of incubation
and stored at
20°C. TNF-
concentrations were measured using
commercially available ELISAs specific for human (R&D Systems) or
monkey (U-Cytech, Utrecht, The Netherlands) TNF-
.
In some experiments, infected DCs were cultured in the presence of 20 µg of neutralizing anti-human TNF-

Abs (R&D Systems)
or control
immunoglobulin G1 (IgG1; PharMingen) per ml. Cell supernatants
were
collected 1 day after infection and analyzed for the presence
of
TNF-

. The DC phenotype was determined at days 1 and 3 by FACS
analysis. Cells cultured for 3 to 4 days had additional Abs added
at
day 2 of
cultures.
 |
RESULTS |
Infection of primate immature and mature DCs by recombinant
ALVAC.
To determine whether DCs could be infected with ALVAC and
to monitor the degree of infection, we chose the construct vCP172. This
enabled us to monitor expression of both ALVAC and SIV antigens in the
exposed DC populations. Mature and immature DCs were infected with
vCP172 (MOI of 10). At multiple time points after infection, cells were
stained intracellularly with either a polyclonal rabbit anti- ALVAC serum or the anti-SIVp27 MAb. Table
1 demonstrates the kinetics of infection
obtained in a representative experiment using human DCs. Immature DCs
exhibited a higher frequency of infection compared to mature DCs. A
considerable percentage, but not all infected DCs (ALVAC positive),
also expressed the protein encoded by the SIV gag gene in
the viral construct. In subsequent experiments infections were mostly
monitored at single time points. However, both human and rhesus macaque
immature DCs always expressed ALVAC-specific proteins to a notably
higher percentage (about two- to fourfold) than mature DCs, and numbers
of ALVAC-positive cells were higher than those of p27-positive DCs
(when infections using vCP172 or vCP180 were analyzed). This might
simply reflect differences in the sensitivity of the Abs or that not
all vCP172-infected, ALVAC-positive cells expressed SIV p27. It was
unlikely that the ALVAC positivity reflected virus bound to the cell
surface, since cells not permeabilized prior to staining were negative
(data not shown).
Immature and mature rhesus macaque DCs were also infected by
recombinant ALVAC (Fig.
1). While
immature DCs were more susceptible
to infection, as seen with human
DCs, the average numbers of infected
macaque cells were as much as
twofold lower than those detected
in human DCs. Immunoperoxidase
staining of cytospins for p27 expression
identified SIV p27-positive
DCs within infected rhesus macaque
and human DCs.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 1.
ALVAC infection of immature DCs and subsequent apoptotic
cell death. (A and B) Immature DCs were infected with vCP172 (MOI of
10). At 24 h after infection, p27 expression was monitored by
either intracellular FACS staining (A, rhesus macaque) or by
immunoperoxidase staining (dark reaction product) on cytospins (B;
magnification, ×1,000). The log fluorescent intensity of FITC (Log
FITC) is shown on the y axes, and the forward light scatter
(FSC) is shown on the x axes. The percentages of
SIV-p27-positive cells (arrowhead), above IgG control, are shown in
panel A. These data are representative of more than five experiments.
(C) vCP172-infected versus uninfected (Medium) immature human DCs were
analyzed for the presence of apoptotic cells using a TUNEL FACS assay
at the indicated times of culture. The percent TUNEL-positive cells at
each time point of one representative experiment of three are shown.
|
|
When vCP172-infected immature DCs were cultured for 3 to 4 days,
considerable cell death was observed. On average, uninfected
cultures
yielded approximately twice the numbers of viable cells
on day 4 compared to infected cultures. This was further supported
by the
reduced forward scatter (size) and increased side scatter
(granularity)
of infected DCs that was evident upon FACS analysis.
To investigate the
mechanism of cell death, infected and uninfected
DCs were harvested at
multiple time points and FACS analysis was
performed to detect
apoptotic, TUNEL-positive cells. Figure
1C
shows the kinetics of the
appearance of TUNEL-positive cells after
infection with ALVAC. These
studies demonstrate a rapid increase
in the numbers of apoptotic cells
shortly after infection of immature
DCs with recombinant
ALVAC.
Infected DCs are phagocytosed by uninfected DCs.
DCs have been
shown to take up dead or dying cells (2, 3). Therefore, we
examined whether the cell fragments from infected dying ALVAC-infected
cells could be phagocytosed by uninfected DCs. CMFDA (green)-stained,
uninfected DCs were cultured with CMTMR (red)-stained infected DCs for
3 days. FACS analysis of the cocultures revealed a significant
proportion of green-red double-positive cells, as well as single green
large cells in contrast to control cultures of uninfected red and
uninfected green DC mixtures (data not shown). Confocal microscopic
analysis of FACS-sorted double-positive or single-positive green
fractions revealed that the double-positive fraction comprised mainly
green (uninfected) cells with large red inclusions (Fig.
2, lower panels). While also many
single-positive green cells contained red inclusions (Fig. 2, upper
panels), they were considerably smaller than those detected in the
double-positive fraction. Internalization of green, uninfected cells by
red, infected DCs was not observed. Therefore, these results suggest
that infected cells dying by apoptosis (Fig. 1C) were phagocytosed by
uninfected DCs.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 2.
Phagocytosis of ALVAC-infected cells by immature,
uninfected DCs. Green-stained, uninfected DCs were cocultured with
red-stained, infected DCs. After 3 days, cells were sorted into
single-positive green cells (top) or double-positive red-green cells
(bottom). The cell populations were further analyzed using confocal
laser scan microscopy. Demonstrated are images yielded with filter
settings for fluorescein only (left), rhodamine only (middle), and with
both images overlaid (right) (magnification, ×1,000).
|
|
DC maturation following ALVAC infection.
When cultures of
ALVAC-infected immature DCs were observed more closely a second
phenomenon was appreciated. Coincident with the cell death induced by
exposure to ALVAC (Fig. 1C), there was a modulation of the DC phenotype
(Fig. 3). Compared to the uninfected controls, increased expression of CD25, CD80, CD83, and CD86 was readily detected in at least a subset of cells after 3 to 4 days. In
both human and monkey, the percentage of canarypox virus-exposed DCs
expressing CD25 varied between donors and ranged between 5 and 35%.
Uninfected control DCs sometimes contained a subset of spontaneously
matured DCs, but this was always considerably smaller than that
observed in ALVAC-infected cultures.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 3.
Maturation of DCs in vCP172-infected cultures. (A)
Immature human DCs were infected with vCP172 (MOI of 10). Infected (+)
and uninfected ( ) DCs were cultured for 4 days. After culture, the
cells were harvested and monitored for the expression of CD25-, CD83-,
and CD86-PE (log PE y axes) versus HLA-DR-FITC
(x axes). The percentage of large cells expressing CD25 and
CD83 above the isotype control are indicated. (B) Immature rhesus
macaque DCs were infected with vCP172 (+) (MOI of 10) or not ( ) and
cultured for 1 to 3 days before being harvested and analyzed. FACS
analysis was performed on cells stained with FITC-anti-HLA-DR versus
PE-immunoglobulin, -anti-CD25, -CD80, -CD83, or -CD86. Similar data
were obtained from more than five experiments with human DCs and three
different monkey donors.
|
|
More detailed examination of infected human and rhesus macaque immature
DCs revealed that maturation could be detected within
1 day of exposure
to the virus (Fig.
3B; see also Fig.
8B). Figure
3B illustrates the
phenotypic changes detected in a rhesus macaque
DC preparation pulsed
with vCP172 1 to 3 days earlier. As early
as 1 day postexposure, the
levels of CD25, CD80, CD83, and CD86
had increased, and this was still
evident at day 3. Although maturation
began by day 1 after infection,
the expression of maturation markers,
particularly CD25, often
increased over the next 2 to 3
days.
To verify that it was the canarypox virus and not the foreign
introduced genes driving maturation, immature DCs were infected
with
vCP180 (containing SIV
gag,
pol, and
env) or with the parental
strain not containing SIV-genes
(ALVAC). Figure
4A shows that
in both
cultures a similar subset of DCs demonstrated increased
CD25 expression
(21 and 19%, respectively). In numerous experiments,
different ALVAC
constructs containing or lacking various viral
genes were used, and
maturation was observed with all constructs
(data not shown). Hence,
canarypox virus itself mediates induction
of DC maturation and not by
foreign genes (or the proteins encoded
by those genes) that have been
engineered into the vectors.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Induction of maturation is stimulated by viable
canarypox virus. (A) Immature human DCs were infected with an MOI of 10 of either vCP180 or the parental strain (ALVAC) or left uninfected
(medium). CD25 surface expression by large HLA-DR-positive cells was
assessed 4 days after infection (CD25-PE, y axes;
HLA-DR-FITC, x axes). The percentage of CD25-positive cells
(above isotype control) are indicated in each panel (highlighted by
arrowheads). (B) Immature human DCs that had been infected with vCP180
3 to 4 days earlier were sorted into CD25-negative (CD25 neg.) and
CD25-positive (CD25 pos.) fractions. Each fraction was then
immunostained for intracellular expression of p27 and analyzed by FACS.
The percentage of SIV p27-positive cells, above the immunoglobulin
control, is shown for each subset. (C) Immature DCs (human) were
infected with live (ALVAC) or heat-inactivated (H.I.) ALVAC or left
untreated (medium). After 4 days the DCs were examined for CD25
expression by FACS. The percentages of CD25-positive large cells
(compared to the isotype control) are shown in each panel. The
CD25-positive subset is highlighted by an arrowhead.
|
|
In an attempt to further characterize the maturing subset within
ALVAC-exposed DC cultures, CD25-positive mature DCs were
separated from
CD25-negative immature DCs by cell sorting 3 to
4 days after infection
with vCP180. Each subset was then analyzed
for the expression of SIV
p27 by intracellular FACS staining.
Considerably fewer p27-positive
cells were detected in the CD25-positive
fraction compared to
CD25-negative cells (Fig.
4B). Hence, viral
infection or gene
expression itself did not seem to be directly
responsible for maturing
the DCs. However, this phenomenon was
dependent on viable virus. Heat
inactivation of virus abrogated
its ability to induce both cell death
and maturation (Fig.
4C).
To exclude the possibility that heat
treatment inactivated a temperature-sensitive
component of the virus
stock that was inducing cell death and/or
the maturation effect,
UV-inactivated virus was also applied to
DCs. As with heat-inactivated
virus, UV-inactivated ALVAC did
not induce DC maturation (data not
shown).
Inhibition of apoptosis partially interferes with maturation.
To investigate whether the induction of apoptotic cell death was a
prerequisite for DC maturation, DCs were treated with the caspase-3
inhibitor Z-DEVD-FMK. Caspase-3 is believed to be involved in all
pathways of apoptotic cell death (37). Immature DCs were pretreated with 250 or 500 µM Z-DEVD-FMK for 30 min. ALVAC was then
added to the wells, and cultures were analyzed 4 days later for CD25
expression as a marker for mature DCs. Figure
5 shows that significantly less CD25
expression was detected in the presence of Z-DEVD-FMK (but not the
diluent control). The addition of Z-DEVD-FMK to MCM-treated immature
DCs did not interfere with MCM-induced maturation (data not shown).
Z-DEVD-FMK did not modify the expression of ALVAC-specific proteins in
exposed cultures as determined by intracellular FACS staining (data not
shown). When apoptosis was monitored in ALVAC-exposed cultures in the
presence of Z-DEVD-FMK, the percentage of TUNEL-positive cells
was reduced by approximately 70% (data not shown), while higher
drug concentrations repeatedly lead to drug-induced cell death. Thus,
blocking apoptotic cell death in the ALVAC-infected cultures reduced
the amount of DC maturation, indicating that the presence of primarily
apoptotic cells rather than a minor population of primarily necrotic
DCs drove DC maturation, at least partially.

View larger version (77K):
[in this window]
[in a new window]
|
FIG. 5.
Inhibition of maturation of ALVAC-infected DCs by the
addition of a caspase 3 inhibitor. A total of 250 or 500 µM
Z-DEVD-FMK, or the equivalent dilution of DMSO diluent for the high
dose (DMSO), were added to immature DCs 30 min before infection with
ALVAC. Inhibition of maturation was assessed by the lack of CD25
expression 4 days after infection using the DMSO-treated cells as the
100% matured population. The data represent the mean percentages of
CD25-expression (% CD25 pos.) of three experiments.
|
|
TNF-
secreted by ALVAC-exposed DCs facilitates DC
maturation.
The previous findings suggested that apoptosis
contributed to maturation. However, even high doses of a caspase-3
inhibitor did not completely reverse the maturation effect of ALVAC
infection (Fig. 5). The evidence that a soluble factor released by
ALVAC-pulsed DCs might contribute to the maturation of healthy DCs was
initially obtained using two different strategies. First, immature DCs
were infected with ALVAC, free virus was washed off, and the infected cells were added to uninfected, immature DCs, which had been previously stained green using CMFDA. After 4 days, DC cultures were monitored for
maturation (CD25-PE staining) in the infected (CMFDA-negative) and
uninfected (CMFDA-positive) populations. Figure
6, upper right, shows that similar
maturation (CD25 expression) was detected in both infected
(CMFDA-negative) and uninfected (CMFDA-positive) DCs. The addition of
supernatant, middle panel, from infected cells harvested directly after
washing out the virus did not change the phenotype of uninfected cells.
Thus, the maturation effect was dependent on the presence of infected
cells, and residual cell-free virus could be excluded as a mediator.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 6.
Maturation of uninfected DCs by ALVAC-infected immature
DCs. Immature DCs were infected with ALVAC, and free virus was washed
out. Uninfected immature DCs that had been stained with the green
fluorescent dye CMFDA were added to the infected (unstained) DCs at a
ratio of 1:1 (Inf. DCs). As controls, the supernatant from infected
cells (collected directly after washing off the virus) was added to
CMFDA-stained cells (Sup't) or the green-uninfected cells were kept in
medium (Medium). Maturation (highlighted by arrowheads) was assessed by
CD25 expression 4 days later. The log PE is expressed on the
y axes (CD25 versus the IgG control), and the CMFDA
fluorescence intensity is expressed on the x axes. The
results from one of two similar experiments are provided.
|
|
A second approach also suggested that soluble products produced by
ALVAC-exposed DCs were able to promote DC maturation. Immature
DCs
cultured on the other side of a porous membrane were induced
to
mature only when ALVAC-infected DCs were present in the opposing
chamber (data not shown). Hence, the infected population released
a
factor(s) that was able to induce maturation of the uninfected
DCs.
TNF-

is secreted in response to viral infections (
44), as
well as being able to induce DC maturation in vitro (
5).
Consequently,
the presence of TNF-

in the ALVAC-infected DC cultures
was investigated.
Cell supernatants were collected from infected and
uninfected
DC cultures 1 to 3 days following exposure to ALVAC.
Significant
TNF-

production occurred within 1 day of exposure of
immature
human DCs to canarypox virus and was dependent on the
infectious
dose used to infect the DCs but was not influenced by the
presence
(or absence) of the foreign genes in the construct (Fig.
7A and
B). Similar TNF-

secretion was
detected in vCP172-infected rhesus
macaque DCs (Fig.
7C).
Interestingly, inclusion of neutralizing
anti-human TNF-

Abs in the
infected human DC cultures resulted
in diminished TNF-

detection and
prevented much of the DC maturation
measured by CD83 expression within
a day of infection (Fig.
8).
Partial
block of DC maturation was also observed at day 3 (data
not shown).
Therefore, TNF-

secreted by immature DCs in response
to infection
with ALVAC contributed significantly to maturation
of uninfected
DCs.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 7.
TNF- secretion by canarypox virus-infected primate
DCs. (A) Immature human DCs were infected with either ALVAC or vCP205
(MOI of 5) or left uninfected (Medium). Cell supernatants were
collected after 24 h and assessed for the presence of TNF- . The
mean TNF- production from three separate experiments using different
donors is shown. (B) Immature human DCs were infected with ALVAC or
vCP205 at the indicated MOIs, and the TNF- production was measured
24 h later. (C) Immature rhesus macaque DCs were pulsed with
vCP172 (MOI of 10) or not (Medium) and cultured for 1 to 3 days. The
TNF- produced after 1 and 3 days is shown for animal R887 and after
1 day for animals M284 and F961.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 8.
Canarypox virus-induced TNF- production facilitates
DC maturation. Immature human DCs were infected or not (Medium) with
vCP205 (MOI of 5) and then incubated in the presence of a blocking
anti-human TNF- Ab or the control isotype immunoglobulin (20 µg/ml). (A) After 18 h the amount of TNF- secreted into the
supernatants was measured by enzyme-linked immunosorbent assay. (B) DCs
were also collected at this time and stained for CD83 expression to
monitor DC maturation. The level of CD83 expression (x axes)
is shown for each of the populations. Medium-treated DCs are shown by a
light gray line, and vCP205 is represented with a dark gray line. The
CD83-positive subset seen in the immunoglobulin-treated, vCP205-pulsed
DCs is indicated with an arrowhead. This subset is lost following
anti-TNF- treatment. The results represent one of three
experiments.
|
|
 |
DISCUSSION |
In recent years there has been an immense increase in the
number of publications investigating the interaction of DCs with various viruses. These encompass measles virus (20, 29, 30, 51,
52, 60), vaccinia virus (14, 16), herpes simplex virus
(47), polyomavirus (13), and most extensively the
immunodeficiency viruses HIV and SIV (7, 9, 23, 26, 31, 41, 42, 62, 65). While DCs may play a role in the pathogenesis of these
infections, they are also likely to be critical in activating virus-specific immune responses. Recombinant avipox virus constructs have proven to be both immunogenic and safe in humans (6, 15, 19,
32, 34, 49) and are, therefore, of great interest in vaccine
research. One study was published on the use of recombinant fowlpox
virus for the transfer of genes to DCs (8). However, little
detail has been placed on understanding the interactions between DCs
and potential viral vectors, nor on what influence such infections
could impart on normal DC function. In the present study, we
investigated the impact of direct in vitro infection of ex vivo
generated DCs with ALVAC in order to determine how to possibly enhance
their immunogenicity for applications in future vaccine development.
Our studies confirmed that significant numbers of immature human
and rhesus macaque DCs could be infected with ALVAC (Table 1 and
Fig. 1A and B). This was comparable to the number of immature DCs that
can be infected by fowlpox virus constructs (8). However, monitoring the infected DCs over the next few days revealed that considerable cell death was detected in cultures of ALVAC-infected immature human and macaque DCs. The major mechanism of death in ALVAC-infected cultures was primarily via apoptosis (Fig. 1C); however,
trypan blue staining also showed that many cells underwent further
secondary necrosis (data not shown). On the other hand, mature DCs
seemed to be more resistant to both viral infection and ALVAC-induced
cell death. This finding was intriguing, especially since the virus was
interacting with a nonpermissive host (mammalian) cells. Furthermore,
similar cytopathic effects were not reported for fowlpox virus-infected
DCs (8). Interestingly, it has recently become clear that
various DNA and RNA viruses can inhibit apoptosis of infected cells.
Such antiapoptotic genes have been reported for various poxviruses such
as vaccinia virus, myxoma virus, and tanapoxvirus (12, 24),
but not for ALVAC. Our results suggest that the cytopathic effects of
ALVAC did not require the completion of the full virus life cycle,
since an abortive infection, as seen in mammalian cells, was effective
in damaging infected immature primate DCs. In contrast, Taylor et al.
have reported (57) no serious side effects after ALVAC
infection of various mammalian cell lines in vitro or following
infection of laboratory animals. Notably, when rabbits or squirrel
monkeys were injected with higher doses of ALVAC via the intradermal
(i.d.) route, temporary poxvirus-like skin lesions developed.
Furthermore, virus was recovered from the injection site for up to 4 days postinjection. This could reflect a similar phenomenon as we
observed in our primary DC system. Considering the high density of
immature DCs in the dermis, DCs may have been infected with the i.d.
injected ALVAC, resulting in DC death thereby contributing to lesion formation.
When infected "red" DCs were cocultured with uninfected "green"
DCs, large red inclusions were detected in the sorted red-green double-positive fraction (Fig. 2). Single green cells contained (at
most) low numbers of much smaller red inclusions. This suggested that
healthy, uninfected DCs had phagocytosed infected, dying DCs. It is
important to note that the double-positive cells showed an
intracellular colocalization of green and red fluorescence, while the
rest of the cell surface seemed rather weakly stained with the green
dye. This most likely indicates that a significant proportion of
green-stained cell membrane of the uninfected DCs was internalized
during the process of phagocytosis. The internalization of the
engulfing cells' membrane with the captured red-labeled infected DC
debris would result in their colocalization within the cell. Because
extensive areas of the residual membrane of the uninfected cells would
have to be renewed, the green staining of the rest of the cell appears
fainter as a result. The mechanism via which the infected DC debris was
internalized is not known. However, one receptor, the
v
5 integrin is primarily expressed by
immature DCs and has been shown to be involved in the uptake of
apoptotic cells by immature DCs (2).
Further analysis revealed that ALVAC infection of primate DCs lead to
the expression of a more mature DC phenotype, i.e., increased levels of
CD25, CD80, CD83, and CD86 (Fig. 3), as well as another DC maturation
marker, DC-LAMP (11) (data not shown). While CD80, CD83, and
CD86 often appeared to be upregulated on the entire DC population, CD25
expression was restricted to a subset of DCs. Recent studies indicated
that the expression of CD25 correlated with a fully differentiated
mature DC phenotype, as monitored by the stabilization of MHC-peptide
complexes on the DC surface (E. Kampgen, 6th International DC Meeting,
May 2000). Therefore, this suggests that at least a subset of DCs was
induced to completely mature following infection with ALVAC, while the
bulk populations appeared to be somewhat activated. Fewer infected
cells were actually detected in the mature CD25-positive fraction
compared to the CD25-negative and CD25-weak subset (Fig. 4B). This
suggests that infection per se was not directly causing DC maturation
in the cultures. The maturation effects were solely mediated by the
virus and not influenced by the presence or absence of foreign genes
(Fig. 4A). Potential contaminants within the virus stocks that could
induce maturation, such as lipopolysaccharide (5) or
mycoplasma (48) were ruled out using the limulus
(BioWhittaker, Walkersville, Md.) and mycoplasma detection (Gen-Probe
Rapid Detection System; Fisher Scientific, Pittsburgh, Pa.) assays
(data not shown).
To clarify whether the presence of apoptotic cells contributed to DC
maturation, we treated the infected cultures with an inhibitor of
apoptosis. Caspases have been found to be the major molecules whose
activation leads to apoptotic cell death (37). Two main
pathways have been described. One involves caspase-8, which is mainly
activated after signaling through receptors belonging to the
Fas/TNF-receptor family. In contrast, the cytochrome
c/Apaf-1 pathway requires caspase-9. Both pathways
ultimately activate caspase-3 as the "effector caspase." Therefore,
we targeted caspase-3 with the inhibitor Z-DEVD-FMK, which has been
shown to block apoptosis in vitro (28). In the presence of
the caspase 3 inhibitor, there was a significantly lower number of DCs
induced to express CD25 following ALVAC exposure (Fig. 5). Hence,
induction of apoptosis as a result of ALVAC infection contributed
significantly to maturation of DCs within these cultures. To date, only
the uptake of necrotic but not primarily apoptotic cells has been shown
to induce DC maturation (21, 50). The contradictions may
reflect differences in the way that the cells were induced to die and,
more importantly, that virus-induced cell death might be very different
to freeze-thaw-induced death. Of note, influenza virus-infected
apoptotic monocytes did also fail to induce DC maturation in those
experiments (50). This could be due to the use of different
virus strains in that study as opposed to our study. Furthermore, as
mentioned above, apoptotic ALVAC-infected DCs subsequently
underwent secondary necrosis, and this also could influence the outcome.
Not all the maturation effect of ALVAC infection was blocked in the
above assays, suggesting either that the inhibition of apoptosis was
incomplete, or that there were additional apoptosis-independent mechanisms inducing DC maturation. Subsequent examination revealed that
ALVAC-mediated TNF-
secretion by immature DCs was a significant player in DC maturation, especially during the early stages (Fig. 7 and
8). Signaling through the TNF receptor family represents one of the
more potent stimuli for DC maturation in vitro and in vivo resulting in
NF-
B activation (5). Interestingly, supernatants from
necrotic cell lines have recently been reported to also induce DC
maturation; however, these supernatants did not contain TNF-
(50). Again, this implies that there might be critical
differences in the manner of DC maturation induced by artificially
"killed" cells and virus-mediated events. While the addition of
anti-TNF Abs, which neutralize both secreted and membrane-bound TNF-
to the ALVAC-infected DCs limited DC maturation, the effect was not 100% (Fig. 8). Therefore, our data suggest that both TNF-
secretion and apoptotic cell death induced by ALVAC infection contribute significantly to the observed DC maturation. It is possible that other
candidate cytokines such as alpha interferon (IFN-
) may be involved.
IFN-
has been shown to act synergistically with TNF-
on DC
maturation (33, 45). In addition, virus-infected cells,
including immature DCs (40, 56), secrete IFN-
. Therefore, we cannot exclude that trace amounts of this and other factors may also
be at work here.
How do our findings relate to how ALVAC behaves in vivo? ALVAC-infected
DCs may act directly and present antigens in vivo. However, it has
recently been shown that if a virus does not target the professional
antigen-presenting cells, the activation of antiviral cytotoxic T cells
requires presentation of exogenous antigen on MHC class I molecules via
the alternative pathway by bone-marrow-derived cells (53).
Additional studies demonstrated that bystander DCs are able to present
bacterial antigens derived from apoptotic Salmonella-infected macrophages in the context of both MHC
class I and class II molecules (64). Therefore,
cross-presentation of viral antigens by DCs which have matured after
engulfing dying infected cells could contribute to the immunogenicity
of ALVAC in mammals. The concomitantly secreted TNF-
could also
induce migration of ALVAC-loaded DCs to the draining lymph nodes
(61) and thereby facilitate immune stimulation. This could
be particularly important when administering ALVAC via the i.d. route.
The skin comprises numerous immature DCs in the epidermis (Langerhans
cells) and dermis (dermal DCs), which would provide suitable targets for injected ALVAC. Of note, the i.d. route is the same route used to
eradicate smallpox using a very similar virus and possibly via similar
mechanisms, since vaccinia virus could be detected in Langerhans cells
at the sites of inoculation (36). In vivo presentation of
ALVAC-borne antigens by DCs is currently under investigation.
 |
ACKNOWLEDGMENTS |
We thank Agegnehu Gettie (Aaron Diamond AIDS Research Center and
Tulane Regional Primate Research Center) and Mark Lewis (Southern Research Institute) for providing rhesus macaque blood samples; Judy
Adams for help with graphics; and Heidi Cleven, Mark Louder, John
Mealy, and David Schaer for expert technical assistance.
This work was supported by the Dorothy Schiff Foundation, the Irma T. Hirschl Trust, and NIH grants AI 40877 and AI 44335 (to M.P.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Cellular Physiology and Immunology, The Rockefeller University, 1230 York Ave., New York, NY 10021. Phone: (212) 327-7794. Fax: (212) 327-7764. E-mail: popem{at}rockvax.rockefeller.edu.
Present address: Department of Medical Microbiology and Infectious
Diseases Immunology, Institute of Infectious Diseases Medicine, Free
University Berlin, 12203 Berlin, Germany.
 |
REFERENCES |
| 1.
|
Abimiku, A. G.,
G. Franchini,
J. Tartaglia,
K. Aldrich,
M. Myagkikh,
P. D. Markham,
P. Chong,
M. Klein,
M. P. Kieny,
E. Paoletti, et al.
1995.
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques.
Nat. Med.
1:321-329[CrossRef][Medline].
|
| 2.
|
Albert, M. L.,
S. F. A. Pearce,
L. M. Francisco,
B. Sauter,
P. Roy,
R. L. Silverstein, and N. Bhardwaj.
1998.
Immature dendritic cells phagocytose apoptotic cells via v 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes.
J. Exp. Med.
188:1359-1368[Abstract/Free Full Text].
|
| 3.
|
Albert, M. L.,
B. Sauter, and N. Bhardwaj.
1998.
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.
Nature
392:86-89[CrossRef][Medline].
|
| 4.
|
Andersson, S.,
B. Makitalo,
R. Thorstensson,
G. Franchini,
J. Tartaglia,
K. Limbach,
E. Paoletti,
P. Putkonen, and G. Biberfeld.
1996.
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys.
J. Infect. Dis.
174:977-985[Medline].
|
| 5.
|
Banchereau, J., and R. M. Steinman.
1998.
Dendritic cells and the control of immunity.
Nature
392:245-252[CrossRef][Medline].
|
| 6.
|
Belshe, R. B.,
G. J. Gorse,
M. J. Mulligan,
T. G. Evans,
M. C. Keefer,
J. L. Excler,
A. M. Duliege,
J. Tartaglia,
W. I. Cox,
J. McNamara,
K. L. Hwang,
A. Bradney,
D. Montefiori, and K. J. Weinhold.
1998.
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
AIDS
12:2407-2415[CrossRef][Medline].
|
| 7.
|
Blauvelt, A.,
H. Asada,
M. W. Saville,
V. Klaus-Kovtun,
D. J. Altman,
R. Yarchoan, and S. I. Katz.
1997.
Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways.
J. Clin. Investig.
100:2043-2053[Medline].
|
| 8.
|
Brown, D.,
D. Davies,
M. Skinner,
G. Bowen,
S. Hollingsworth,
G. Mufti,
J. Arrand, and S. Stacey.
1999.
Antigen transfer to cultured human dendritic cells using recombinant avipoxvirus vectors.
Cancer Gene Ther.
6:238-245[CrossRef][Medline].
|
| 9.
|
Cameron, P. U.,
P. S. Freudenthal,
J. M. Barker,
S. Gezelter,
K. Inaba, and R. M. Steinman.
1992.
Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells.
Science
257:383-387.
|
| 10.
|
Clements-Mann, M. L.,
K. Weinhold,
T. J. Matthews,
B. S. Graham,
G. J. Gorse,
M. C. Keefer,
M. J. McElrath,
R. H. Hsieh,
J. Mestecky,
S. Zolla-Pazner,
J. Mascola,
D. Schwartz,
R. Siliciano,
L. Corey,
P. F. Wright,
R. Belshe,
R. Dolin,
S. Jackson,
S. Xu,
P. Fast,
M. C. Walker,
D. Stablein,
J. L. Excler,
J. Tartaglia,
E. Paoletti, et al.
1998.
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
J. Infect. Dis.
177:1230-1246[Medline].
|
| 11.
|
de Saint-Vis, B.,
J. Vincent,
S. Vandenabeele,
B. Vanbervliet,
J.-J. Pin,
S. Ait-Yahia,
S. Patel,
M.-G. Mattei,
J. Banchereau,
S. Zurawski,
J. Davoust,
C. Caux, and S. Lebecque.
1998.
A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment.
Immunity
9:325-336[CrossRef][Medline].
|
| 12.
|
Dobbelstein, M., and T. Shenk.
1996.
Protection against apoptosis by the vaccinia virus SPI-2 [B13R] gene product.
J. Virol.
70:6479-6485[Abstract].
|
| 13.
|
Drake, D. R., III,
J. M. Moser,
A. Hadley,
J. D. Altman,
C. Maliszewski,
E. Butz, and A. E. Lukacher.
2000.
Polyomavirus-infected dendritic cells induce antiviral CD8+ T lymphocytes.
J. Virol.
74:4093-4101[Abstract/Free Full Text].
|
| 14.
|
Drillien, R.,
D. Spehner,
A. Bohbot, and D. Hanau.
2000.
Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes.
Virology
268:471-481[CrossRef][Medline].
|
| 15.
|
Egan, M. A.,
W. A. Pavlat,
J. Tartaglia,
E. Paoletti,
K. J. Weinhold,
M. L. Clements, and R. F. Siliciano.
1995.
Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.
J. Infect. Dis.
171:1623-1627[Medline].
|
| 16.
|
Engelmayer, J.,
M. Larsson,
M. Subklewe,
A. Chahroudi,
A. Schmaljohn,
C. William,
R. M. Steinman, and N. Bhardwaj.
1999.
Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion.
J. Immunol.
163:6762-6768[Abstract/Free Full Text].
|
| 17.
|
Fischer, L.,
F. X. Le Gros,
P. W. Mason, and E. Paoletti.
1997.
A recombinant canarypox virus protects rabbits against a lethal rabbit hemorrhagic disease virus (RHDV) challenge.
Vaccine
15:90-96[CrossRef][Medline].
|
| 18.
|
Franchini, G.,
M. Robert-Guroff,
J. Tartaglia,
A. Aggarwal,
A. Abimiku,
J. Benson,
P. Markham,
K. Limbach,
G. Hurteau,
J. Fullen,
M. Wills,
J. Arp,
G. Dekaban,
E. Paoletti, and R. C. Gallo.
1995.
Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques.
AIDS Res. Hum. Retrovir.
11:909-920[Medline].
|
| 19.
|
Fries, L. F.,
J. Tartaglia,
J. Taylor,
E. K. Kauffman,
B. Meignier,
E. Paoletti, and S. Plotkin.
1996.
Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system.
Vaccine
14:428-434[CrossRef][Medline].
|
| 20.
|
Fugier-Vivier, I.,
P. Rivailler,
M.-C. Rissoan,
Y.-J. Liu,
C. Rabourdin-Combe,
S. O. Warnarr,
C. J. H. van de Velde, and C. J. M. Melief.
1997.
Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells.
J. Exp. Med.
186:813-823[Abstract/Free Full Text].
|
| 21.
|
Gallucci, S.,
M. Lolkema, and P. Matzinger.
1999.
Natural adjuvants: endogenous activators of dendritic cells.
Nat. Med.
5:1249-1255[CrossRef][Medline].
|
| 22.
|
Geijtenbeek, T. B. H.,
D. S. Kwon,
R. Torensma,
S. J. van Vliet,
G. C. F. van Duijnhoven,
J. Middel,
I. L. M. H. A. Cornelissen,
H. S. L. M. Nottet,
V. N. KewalRamani,
D. R. Littman,
C. G. Figdor, and Y. van Kooyk.
2000.
DC-SIGN, a dendritic cell specific HIV-1 binding protein that enhances TRANS-infection of T cells.
Cell
100:587-597[CrossRef][Medline].
|
| 23.
|
Granelli-Piperno, A.,
M. Pope,
K. Inaba, and R. M. Steinman.
1995.
Coexpression of NFKB/ReL and Sp1 transcription factors in HIV-1 induced, dendritic cell-T cell syncytia.
Proc. Natl. Acad. Sci. USA
92:10944-10948[Abstract/Free Full Text].
|
| 24.
|
Herbein, G., and W. A. O'Brien.
2000.
Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis.
Proc. Soc. Exp. Biol. Med.
223:241-257[Abstract/Free Full Text].
|
| 25.
|
Hodge, J. W.,
J. P. McLaughlin,
J. A. Kantor, and J. Schlom.
1997.
Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
Vaccine
15:759-768[CrossRef][Medline].
|
| 26.
|
Ignatius, R.,
F. Isdell,
U. O'Doherty, and M. Pope.
1998.
Dendritic cells from skin and blood of macaques both promote SIV replication with T cells from different anatomical sites.
J. Med. Primatol.
27:121-128[Medline].
|
| 27.
|
Inaba, K.,
S. Turley,
F. Yamaide,
T. Iyoda,
K. Mahnke,
M. Inaba,
M. Pack,
M. Subklewe,
B. Sauter,
D. Sheff,
M. Albert,
N. Bhardwaj,
I. Mellman, and R. M. Steinman.
1998.
Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells.
J. Exp. Med.
188:2163-2173[Abstract/Free Full Text].
|
| 28.
|
Kasai, T.,
K. Ohguchi,
S. Nakashima,
Y. Ito,
T. Naganawa,
N. Kondo, and Y. Nozawa.
1998.
Increased activity of oleate-dependent type phospholipase D during actinomycin D-induced apoptosis in Jurkat T cells.
J. Immunol.
161:6469-6474[Abstract/Free Full Text].
|
| 29.
|
Kitov, P. I.,
J. M. Sadowska,
G. Mulvey,
G. D. Armstrong,
H. Ling,
N. S. Pannu,
R. J. Read, and D. R. Bundle.
2000.
Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands.
Nature
403:669-672[CrossRef][Medline].
|
| 30.
|
Klagge, I. M., and S. Schneider-Schaulies.
1999.
Virus interactions with dendritic cells.
J. Gen. Virol.
80:823-833[Medline].
|
| 31.
|
Knight, S. C.,
S. E. Macatonia, and S. Patterson.
1990.
HIV-1 infection of dendritic cells.
Int. Rev. Immunol.
6:163-175[Medline].
|
| 32.
|
Konishi, E.,
I. Kurane,
P. W. Mason,
R. E. Shope,
N. Kanesa-Thasan,
J. J. Smucny,
C. H. Hoke, Jr., and F. A. Ennis.
1998.
Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates.
Vaccine
16:842-849[CrossRef][Medline]. (Erratum, 17:I, 1999.)
|
| 33.
|
Luft, T.,
K. C. Pang,
E. Thomas,
P. Hertzog,
D. N. J. Hart,
J. Trapani, and J. Cebon.
1998.
Type I IFNs enhance the terminal differentiation of dendritic cells.
J. Immunol.
161:1947-1953[Abstract/Free Full Text].
|
| 34.
|
Marshall, J. L.,
M. J. Hawkins,
K. Y. Tsang,
E. Richmond,
J. E. Pedicano,
M. Z. Zhu, and J. Schlom.
1999.
Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.
J. Clin. Oncol.
17:332-337[Abstract/Free Full Text].
|
| 35.
|
Myagkikh, M.,
S. Alipanah,
P. D. Markham,
J. Tartaglia,
E. Paoletti,
R. C. Gallo,
G. Franchini, and M. Robert-Guroff.
1996.
Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques.
AIDS Res. Hum. Retrovir.
12:985-992[Medline].
|
| 36.
|
Nagao, S.,
S. Inaba, and S. Iijima.
1976.
Langerhans cells at the sites of vaccinia virus inoculation.
Arch. Dermatol. Res.
256:23-31[CrossRef][Medline].
|
| 37.
|
Nunez, G.,
M. A. Benedict,
Y. Hu, and N. Inohara.
1998.
Caspases: the proteases of the apoptotic pathway.
Oncogene
17:3237-3245[CrossRef][Medline].
|
| 38.
|
Paoletti, E.
1996.
Applications of pox virus vectors to vaccination: an update.
Proc. Natl. Acad. Sci. USA
93:11354-11358[Abstract/Free Full Text].
|
| 39.
|
Pardo, M. C.,
J. E. Bauman, and M. Mackowiak.
1997.
Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins.
Am. J. Vet. Res.
58:833-836[Medline].
|
| 40.
|
Pfeffer, L. M.,
C. A. Dinarello,
R. B. Herberman,
B. R. Williams,
E. C. Borden,
R. Bordens,
M. R. Walter,
T. L. Nagabhushan,
P. P. Trotta, and S. Pestka.
1998.
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Cancer Res.
58:2489-2499[Abstract/Free Full Text].
|
| 41.
|
Pope, M.,
M. G. H. Betjes,
N. Romani,
H. Hirmand,
P. U. Cameron,
L. Hoffman,
S. Gezelter,
G. Schuler, and R. M. Steinman.
1994.
Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1.
Cell
78:389-398[CrossRef][Medline].
|
| 42.
|
Pope, M.,
D. Elmore,
D. Ho, and P. Marx.
1997.
Dendritic cell T cell mixtures, isolated from the skin and mucosae of macaques, support the replication of SIV.
AIDS Res. Hum. Retrovir.
13:819-827[Medline].
|
| 43.
|
Raengsakulrach, B.,
A. Nisalak,
M. Gettayacamin,
V. Thirawuth,
G. D. Young,
K. S. A. Myint,
L. M. Ferguson,
C. H. Hoke,
B. L. Innis, and D. W. Vaughn.
1999.
An intranasal challenge model for testing Japanese encephalitis vaccines in rhesus monkeys.
Am. J. Trop. Med. Hyg.
60:329-337[Abstract].
|
| 44.
|
Ramshaw, I. A.,
A. J. Ramsay,
G. Karupiah,
M. S. Rolph,
S. Mahalingam, and J. C. Ruby.
1997.
Cytokines and immunity to viral infections.
Immunol. Rev.
159:119-135[CrossRef][Medline].
|
| 45.
|
Reddy, A.,
M. Sapp,
M. Feldman,
M. Subklewe, and N. Bhardwaj.
1997.
A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells.
Blood
90:3640-3646[Abstract/Free Full Text].
|
| 46.
|
Roth, J.,
D. Dittmer,
D. Rea,
J. Tartaglia,
E. Paoletti, and A. J. Levine.
1996.
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.
Proc. Natl. Acad. Sci. USA
93:4781-4786[Abstract/Free Full Text].
|
| 47.
|
Salio, M.,
M. Cella,
M. Suter, and A. Lanzavecchia.
1999.
Inhibition of dendritic cell maturation by herpes simplex virus.
Eur. J. Immunol.
29:3245-3253[CrossRef][Medline].
|
| 48.
|
Salio, M.,
V. Cerundolo, and A. Lanzavecchia.
2000.
Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells.
Eur. J. Immunol.
30:705-708[CrossRef][Medline].
|
| 49.
|
Salmon-Ceron, D.,
J. L. Excler,
L. Finkielsztejn,
B. Autran,
J. C. Gluckman,
D. Sicard,
T. J. Matthews,
B. Meignier,
C. Valentin,
R. El Habib,
C. Blondeau,
M. Raux,
C. Moog,
J. Tartaglia,
P. Chong,
M. Klein,
B. Milcamps,
F. Heshmati, and S. Plotkin.
1999.
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
AIDS Res. Hum. Retrovir.
15:633-645[CrossRef][Medline].
|
| 50.
|
Sauter, B.,
M. L. Albert,
L. Francisco,
M. Larsson,
S. Somersan, and N. Bhardwaj.
2000.
Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.
J. Exp. Med.
191:423-434[Abstract/Free Full Text].
|
| 51.
|
Schnorr, J.-J.,
S. Xanthakos,
P. Keikavoussi,
E. Kämpgen,
V. T. Meulen, and S. Schneider-Schaulies.
1997.
Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression.
Proc. Natl. Acad. Sci. USA
94:5326-5331[Abstract/Free Full Text].
|
| 52.
|
Servet-Delprat, C.,
P. O. Vidalain,
O. Azocar,
F. Le Deist,
A. Fischer, and C. Rabourdin-Combe.
2000.
Consequences of Fas-mediated human dendritic cell apoptosis induced by measles virus.
J. Virol.
74:4387-4393[Abstract/Free Full Text].
|
| 53.
|
Sigal, L. J.,
S. Crotty,
R. Andino, and K. L. Rock.
1999.
Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen.
Nature
398:77-80[CrossRef][Medline].
|
| 54.
|
Steinman, R. M.
1991.
The dendritic cell system and its role in immunogenicity.
Annu. Rev. Immunol.
9:271-296[CrossRef][Medline].
|
| 55.
|
Stephensen, C. B.,
J. Welter,
S. R. Thaker,
J. Taylor,
J. Tartaglia, and E. Paoletti.
1997.
Canine distemper virus (CDV) infection of ferrets as a model for testing morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection.
J. Virol.
71:1506-1513[Abstract].
|
| 56.
|
Svensson, H.,
A. Johannisson,
T. Nikkila,
G. V. Alm, and B. Cederblad.
1996.
The cell surface phenotype of human natural interferon-alpha producing cells as determined by flow cytometry.
Scand. J. Immunol.
44:164-172[CrossRef][Medline].
|
| 57.
|
Taylor, J.,
B. Meignier,
J. Tartaglia,
B. Languet,
J. VanderHoeven,
G. Franchini,
C. Trimarchi, and E. Paoletti.
1995.
Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.
Vaccine
13:539-549[CrossRef][Medline].
|
| 58.
|
Taylor, J.,
C. Trimarchi,
R. Weinberg,
B. Languet,
F. Guillemin,
P. Desmettre, and E. Paoletti.
1991.
Efficacy studies on a canarypox-rabies recombinant virus.
Vaccine
9:190-193[CrossRef][Medline].
|
| 59.
|
Tellier, M. C.,
R. Pu,
D. Pollock,
A. Vitsky,
J. Tartaglia,
E. Paoletti, and J. K. Yamamoto.
1998.
Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
AIDS
12:11-18[CrossRef][Medline].
|
| 60.
|
Vidalain, P. O.,
O. Azocar,
B. Lamouille,
A. Astier,
C. Rabourdin-Combe, and C. Servet-Delprat.
2000.
Measles virus induces functional TRAIL production by human dendritic cells.
J. Virol.
74:556-559[Abstract/Free Full Text].
|
| 61.
|
Wang, B.,
H. Fujisawa,
L. Zhuang,
S. Kondo,
G. M. Shivji,
C. S. Kim,
T. W. Mak, and D. N. Sauder.
1997.
Depressed Langerhans cell migration and reduced contact hypersensitivity response in mice lacking TNF receptor p75.
J. Immunol.
159:6148-6155[Abstract].
|
| 62.
|
Weissman, D.,
Y. Li,
J. Ananworanich,
L.-J. Zhou,
J. Adelsberger,
T. F. Tedder,
M. Baseler, and A. S. Fauci.
1995.
Three populations of cells with dendritic morphology exist in peripheral blood, only one of which is infectable with human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
92:826-830[Abstract/Free Full Text].
|
| 63.
|
Welter, J.,
J. Taylor,
J. Tartaglia,
E. Paoletti, and C. B. Stephensen.
1999.
Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection.
Vaccine
17:308-318[CrossRef][Medline].
|
| 64.
|
Yrlid, U., and M. J. Wick.
2000.
Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells.
J. Exp. Med.
191:613-623[Abstract/Free Full Text].
|
| 65.
|
Zoeteweij, J. P., and A. Blauvelt.
1998.
HIV-Dendritic cell interactions promote efficient viral infection of T cells.
J. Biomed. Sci.
5:253-259[CrossRef][Medline].
|
Journal of Virology, December 2000, p. 11329-11338, Vol. 74, No. 23
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Maness, N. J., Sacha, J. B., Piaskowski, S. M., Weisgrau, K. L., Rakasz, E. G., May, G. E., Buechler, M. B., Walsh, A. D., Wilson, N. A., Watkins, D. I.
(2009). Novel Translation Products from Simian Immunodeficiency Virus SIVmac239 Env-Encoding mRNA Contain both Rev and Cryptic T-Cell Epitopes. J. Virol.
83: 10280-10285
[Abstract]
[Full Text]
-
Trapp, S., Derby, N. R., Singer, R., Shaw, A., Williams, V. G., Turville, S. G., Bess, J. W. Jr., Lifson, J. D., Robbiani, M.
(2009). Double-Stranded RNA Analog Poly(I:C) Inhibits Human Immunodeficiency Virus Amplification in Dendritic Cells via Type I Interferon-Mediated Activation of APOBEC3G. J. Virol.
83: 884-895
[Abstract]
[Full Text]
-
Jasny, E., Eisenblatter, M., Matz-Rensing, K., Tenner-Racz, K., Tenbusch, M., Schrod, A., Stahl-Hennig, C., Moos, V., Schneider, T., Racz, P., Uberla, K., Kaup, F.-J., Ignatius, R.
(2008). IL-12-Impaired and IL-12-Secreting Dendritic Cells Produce IL-23 upon CD154 Restimulation. J. Immunol.
180: 6629-6639
[Abstract]
[Full Text]
-
Johansson, U., Walther-Jallow, L., Smed-Sorensen, A., Spetz, A.-L.
(2007). Triggering of Dendritic Cell Responses after Exposure to Activated, but Not Resting, Apoptotic PBMCs. J. Immunol.
179: 1711-1720
[Abstract]
[Full Text]
-
Zhang, X., Cassis-Ghavami, F., Eller, M., Currier, J., Slike, B. M., Chen, X., Tartaglia, J., Marovich, M., Spearman, P.
(2007). Direct Comparison of Antigen Production and Induction of Apoptosis by Canarypox Virus- and Modified Vaccinia Virus Ankara-Human Immunodeficiency Virus Vaccine Vectors. J. Virol.
81: 7022-7033
[Abstract]
[Full Text]
-
Sun, P., Celluzzi, C. M., Marovich, M., Subramanian, H., Eller, M., Widjaja, S., Palmer, D., Porter, K., Sun, W., Burgess, T.
(2006). CD40 Ligand Enhances Dengue Viral Infection of Dendritic Cells: A Possible Mechanism for T Cell-Mediated Immunopathology. J. Immunol.
177: 6497-6503
[Abstract]
[Full Text]
-
Deng, L., Dai, P., Ding, W., Granstein, R. D., Shuman, S.
(2006). Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells.. J. Virol.
80: 9977-9987
[Abstract]
[Full Text]
-
Yuan, J., Latouche, J.-B., Hodges, J., Houghton, A. N., Heller, G., Sadelain, M., Riviere, I., Young, J. W.
(2006). Langerhans-Type Dendritic Cells Genetically Modified to Express Full-Length Antigen Optimally Stimulate CTLs in a CD4-Dependent Manner. J. Immunol.
176: 2357-2365
[Abstract]
[Full Text]
-
Peretti, S., Shaw, A., Blanchard, J., Bohm, R., Morrow, G., Lifson, J. D., Gettie, A., Pope, M.
(2005). Immunomodulatory effects of HSV-2 infection on immature macaque dendritic cells modify innate and adaptive responses. Blood
106: 1305-1313
[Abstract]
[Full Text]
-
Triozzi, P. L., Allen, K. O., Carlisle, R. R., Craig, M., LoBuglio, A. F., Conry, R. M.
(2005). Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma. Clin. Cancer Res.
11: 4168-4175
[Abstract]
[Full Text]
-
Palmer, D. R., Sun, P., Celluzzi, C., Bisbing, J., Pang, S., Sun, W., Marovich, M. A., Burgess, T.
(2005). Differential Effects of Dengue Virus on Infected and Bystander Dendritic Cells. J. Virol.
79: 2432-2439
[Abstract]
[Full Text]
-
Drillien, R., Spehner, D., Hanau, D.
(2004). Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J. Gen. Virol.
85: 2167-2175
[Abstract]
[Full Text]
-
Fleeton, M. N., Contractor, N., Leon, F., Wetzel, J. D., Dermody, T. S., Kelsall, B. L.
(2004). Peyer's Patch Dendritic Cells Process Viral Antigen from Apoptotic Epithelial Cells in the Intestine of Reovirus-infected Mice. JEM
200: 235-245
[Abstract]
[Full Text]
-
Yu, Q., Kovacs, C., Yue, F. Y., Ostrowski, M. A.
(2004). The Role of the p38 Mitogen-Activated Protein Kinase, Extracellular Signal-Regulated Kinase, and Phosphoinositide-3-OH Kinase Signal Transduction Pathways in CD40 Ligand-Induced Dendritic Cell Activation and Expansion of Virus-Specific CD8+ T Cell Memory Responses . J. Immunol.
172: 6047-6056
[Abstract]
[Full Text]
-
Tulman, E. R., Afonso, C. L., Lu, Z., Zsak, L., Kutish, G. F., Rock, D. L.
(2004). The Genome of Canarypox Virus. J. Virol.
78: 353-366
[Abstract]
[Full Text]
-
Cappello, P., Caorsi, C., Bosticardo, M., De Angelis, S., Novelli, F., Forni, G., Giovarelli, M.
(2004). CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. J. Leukoc. Biol.
75: 135-142
[Abstract]
[Full Text]
-
Brown, K., Gao, W., Alber, S., Trichel, A., Murphey-Corb, M., Watkins, S. C., Gambotto, A., Barratt-Boyes, S. M.
(2003). Adenovirus-Transduced Dendritic Cells Injected into Skin or Lymph Node Prime Potent Simian Immunodeficiency Virus-Specific T Cell Immunity in Monkeys. J. Immunol.
171: 6875-6882
[Abstract]
[Full Text]
-
Wang, X., Messerle, M., Sapinoro, R., Santos, K., Hocknell, P. K., Jin, X., Dewhurst, S.
(2003). Murine Cytomegalovirus Abortively Infects Human Dendritic Cells, Leading to Expression and Presentation of Virally Vectored Genes. J. Virol.
77: 7182-7192
[Abstract]
[Full Text]
-
Spetz, A.-L., Sorensen, A. S., Walther-Jallow, L., Wahren, B., Andersson, J., Holmgren, L., Hinkula, J.
(2002). Induction of HIV-1-Specific Immunity After Vaccination with Apoptotic HIV-1/Murine Leukemia Virus-Infected Cells. J. Immunol.
169: 5771-5779
[Abstract]
[Full Text]
-
Humlova, Z., Vokurka, M., Esteban, M., Melkova, Z.
(2002). Vaccinia virus induces apoptosis of infected macrophages. J. Gen. Virol.
83: 2821-2832
[Abstract]
[Full Text]
-
Messmer, D., Jacque, J.-M., Santisteban, C., Bristow, C., Han, S.-Y., Villamide-Herrera, L., Mehlhop, E., Marx, P. A., Steinman, R. M., Gettie, A., Pope, M.
(2002). Endogenously Expressed nef Uncouples Cytokine and Chemokine Production from Membrane Phenotypic Maturation in Dendritic Cells. J. Immunol.
169: 4172-4182
[Abstract]
[Full Text]
-
Li, L., Liu, D., Hutt-Fletcher, L., Morgan, A., Masucci, M. G., Levitsky, V.
(2002). Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood
99: 3725-3734
[Abstract]
[Full Text]
-
Frank, I., Piatak, M. Jr., Stoessel, H., Romani, N., Bonnyay, D., Lifson, J.D., Pope, M.
(2002). Infectious and Whole Inactivated Simian Immunodeficiency Viruses Interact Similarly with Primate Dendritic Cells (DCs): Differential Intracellular Fate of Virions in Mature and Immature DCs. J. Virol.
76: 2936-2951
[Abstract]
[Full Text]
-
Zhao, X.-Q., Huang, X.-L., Gupta, P., Borowski, L., Fan, Z., Watkins, S. C., Thomas, E. K., Rinaldo, C. R. Jr.
(2002). Induction of Anti-Human Immunodeficiency Virus Type 1 (HIV-1) CD8+ and CD4+ T-Cell Reactivity by Dendritic Cells Loaded with HIV-1 X4-Infected Apoptotic Cells. J. Virol.
76: 3007-3014
[Abstract]
[Full Text]
-
Arrode, G., Boccaccio, C., Abastado, J.-P., Davrinche, C.
(2002). Cross-Presentation of Human Cytomegalovirus pp65 (UL83) to CD8+ T Cells Is Regulated by Virus-Induced, Soluble-Mediator-Dependent Maturation of Dendritic Cells. J. Virol.
76: 142-150
[Abstract]
[Full Text]